Advances in the targeting ATP-binding cassette transporters to overcome tumor multi-drug resistance

Yaoxue Xuebao

Volumn 45, Issue 10, 2010, Pages 1205-1211

  Wei, Ning ^a   Sun, Hua ^a   Liu, Geng Tao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

ABC transporter; Breast cancer resistance protein; Multi drug resistance; Multi drug resistance associated protein; P glycoprotein

Indexed keywords

ABC TRANSPORTER;

DRUG MECHANISM; HUMAN; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 78650197220     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants [J]. Biochim Biophys Acta, 1976, 455: 152-162.
2. Gottesman MM, Fojo T, Bates SE. Targeting multidrug resistance in cancer [J]. Nat Rev Cancer, 2006, 5: 219-234.
3. Stephen GA, Jodie Y, Andrew W, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding [J]. Science, 2009, 323: 1718-1722.
4. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal [J]. Cancer Cell Int, 2005, 5: 30.
5. Cole SP, Bhardwaj G, Gerlach JH, et al. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line [J]. Science, 1992, 5088: 1650-1654. (Pubitemid 23012438)
6. Lage H. An overview of cancer multidrug resistance: a still unsolved problem [J]. Cell Mol Life Sci, 2008, 65: 3145-3167.
7. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells [J]. Proc Natl Acad Sci USA. 1998, 95: 15665-15670.
8. Helen MC. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer [J]. Cancer Treat Rev, 2008, 34: 378-390.
9. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells [J]. Stem Cells, 2002, 20: 11-20.
10. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues [J]. Proc Natl Acad Sci USA, 1987, 84: 265-269.
11. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer [J]. Br J Cancer, 1999, 63: 663-669.
12. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance associated proteins 1 and 2, and multidrug resistance gene1 in breast cancer correlation with chemotherapeutic response [J]. Clin Cancer Res, 2003, 9: 827-836.
13. Oda Y, Saito T, Tateishi N, et al. ATP-binding cassette super-family transporter gene expression in human soft tissue sarcomas [J]. Int J Cancer, 2005, 114: 854-862.
14. Nooter K, Brutel RG, Look MP, et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer [J]. Br J Cancer, 1997, 76: 486-493.
15. Leonessa F, Clarke R. ATP-binding cassette transporters and drug resistance in breast cancer [J]. Endocr Relat Cancer, 2003, 10: 43-73.
16. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy [J]. Lung Cancer, 2008, 25: 312-319.
17. Yuan J, Lü H, Peng B, et al. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer [J]. Cancer Chemother Pharmacol, 2008, 27: 151-156.
18. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil [J]. Cancer Res, 1981, 41: 1967-1972.
19. Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar) [J]. Cancer, 2001, 92: 1577-1590.
20. Minderman H, O'Loughlin KL, Pendyala L, et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein [J]. Clin Cancer Res, 2004, 10: 1826-1834. (Pubitemid 38435574)
21. Gandhi L, Harding MW, Neubauer M, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer [J]. Cancer, 2007, 109: 924-932.
22. Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research [J]. Drugs, 2002, 5: 349-355.
23. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities [J]. Pharmacol Exp Ther, 1999, 290: 854-862.
24. Morschhauser F, Zinzani PL, Burgess M, et al. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HC1 trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma [J]. Leuk Lymphoma, 2007, 48: 708-715.
25. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor [J]. Expert Rev Anticancer Ther, 2007, 7: 447-459.
26. Robey RW, Shukla S, Finley EM, et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)) [J]. Biochem Pharmacol, 2008, 75: 1302-1312.
27. Kitazaki T, Oka M, Nakamura Y, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells [J]. Lung Cancer, 2005, 49: 337-343.
28. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 [J]. Cancer Res, 2008, 68: 7905-7914.
29. Shi Z, Tiwari AK, Shukla S, et al. Inhibiting the function of ABCBl and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478 [J]. Biochem Pharmacol, 2009, 77: 781-793.
30. Tao LY, Liang YJ, Wang F, et al. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function [J]. Cancer Chemother Pharmacol, 2009, 64: 961-969.
31. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 [J]. Leukemia, 2004, 18: 1246-1251.
32. Kim SN, Kim NH, Lee W, et al. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region [J]. Mol Cancer Res, 2009, 7: 735-744.
33. Zhao X, Gu J, Yin D, et al. Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer [J]. Bioorg Med Chem Lett, 2004, 14: 4767-4770.
34. Liu XD, Sun H, Liu GT. 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Be17402 cells [J]. Cancer Lett, 2010, 292: 24-31.
35. Jin J, Wang FP, Liu GT. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine [J]. Cancer Chemother Pharmacol, 2005, 55: 179-188.
36. Chen LM, Liang YJ, Zhang X, et al. Reversal of P-gpmediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue [J]. Anticancer Res, 2009, 29: 4597-4604.
37. Wei N, Sun H, Wang FP, et al. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein [J]. Cancer Chemother Pharmacol, 2010, in press.
38. Zhang YH, Wu Q, Xiao XY, et al. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell [J]. Cancer Lett, 2010, 291: 76-82.
39. Lü H, He Z, Liu X, et al. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs [J]. J Cell Biochem, 2007, 102: 75-81.
40. Ye X, Liu T, Gong Y, et al. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1 [J]. Leuk Res, 2009, 33: 1114-1119.
41. Zhang X, Li J, Qiu Z, et al. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi) [J]. Cancer Biol Ther, 2009, 8: 1117-1121.
42. Guo H, Jiang W, Liu W, et al. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia [J]. Leukemia, 2004, 18: 513-520.
43. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies [J]. Curr Mol Pharmacol, 2008, 1: 93-105.
44. Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma [J]. Plos One, 2010, 5: e10764.
45. Bartosiewicz D, Krasowska A. Inhibitors of ABC transporters and biophysical methods to study their activity [J]. Z Naturforsch C, 2009, 64: 454-458.
46. Wang YZ, Fang XL, Li YJ, et al. Preparation, characterization of paclitaxel-loaded pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor [J]. Acta Pharm Sin, 2008, 43: 640-646.
47. 4 and Au with daunomycin on K562/A02 cells [J]. Int J Nanomed, 2008, 3: 343-350.
48. Chen JN, Shen Q, Li SS. Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance [J]. Acta Pharm Sin, 2009, 44: 333-337.
49. Diao YY, Han M, Chen DW, et al. Progress in the study of micelle delivery system reversing multidrug resistance [J]. Acta Pharm Sin, 2009, 44: 710-715.